Outlook Therapeutics to Present at Wet AMD and DME Drug Development Summit
April 05 2022 - 7:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to develop and launch the first FDA-approved
ophthalmic formulation of bevacizumab for use in retinal
indications, today announced that Russ Trenary, President and Chief
Executive Officer of Outlook Therapeutics, will be presenting at
the Wet AMD and DME Drug Development Summit taking place April 5-7,
2022 in Boston, Massachusetts.
Details for the presentation are as follows:
Session: Seeking Improved Therapeutics for Wet AMD &
DME Patients Title: Enhancing the Standard of Care
in Wet AMD, BRVO, & DMEPresenter: Russ Trenary,
President and CEO, Outlook TherapeuticsDate and
Time: Wednesday, April 6, 2022, 9:45 AM EST
For more information, please visit
wet-amd-drugdevelopment.com.About Outlook
Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical
company working to develop and launch ONS-5010/ LYTENAVA™
(bevacizumab-vikg), an investigational therapy, as the first
FDA-approved ophthalmic formulation of bevacizumab for use in
retinal indications, including wet AMD, DME and BRVO. Outlook
Therapeutics has submitted its Biologics License Application
(BLA) to the U.S. Food and Drug Administration (FDA) for
ONS-5010 to treat wet AMD. The submission is supported by Outlook
Therapeutics’ wet AMD registration clinical program, which consists
of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If
ONS-5010 ophthalmic bevacizumab is approved, Outlook
Therapeutics expects to commercialize it as the first and only
FDA-approved ophthalmic formulation of bevacizumab for use in
treating retinal diseases in the United States, United
Kingdom, Europe, Japan and other markets. For more
information, please visit www.outlooktherapeutics.com.
CONTACTS:Media
Inquiries:Harriet UllmanVice PresidentLaVoie Health
ScienceT: 617-669-3082hullman@lavoiehealthscience.com
Investor
Inquiries: Jenene
ThomasChief Executive OfficerJTC Team, LLCT:
833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Apr 2024 to May 2024
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From May 2023 to May 2024